Kolon TissueGene Rises for 6th Consecutive Trading Day... Recovery to 30,000 Won vs. Short-Term Correction 'Key Watchpoint'
Kolon TissueGene (950160) is drawing market attention as it records gains for six consecutive trading days, with focus on whether the stock can recover the 30,000 won level. As of 11:31 a.m. on the 14th, Kolon TissueGene is trading at 26,775 won, up 1,175 won (4.59%) from the previous trading day.

Kolon TissueGene (950160) is drawing market attention as it records gains for six consecutive trading days, with focus on whether the stock can recover the 30,000 won level.
As of 11:31 a.m. on the 14th, Kolon TissueGene is trading at 26,775 won, up 1,175 won (4.59%) from the previous trading day. During the session, the stock rose to as high as 27,800 won, approaching the 28,000 won level. On the previous trading day, the 13th, the stock also showed a double-digit intraday gain, continuing a strong rebound trend.
Kolon TissueGene has maintained an upward trend for six consecutive trading days from the 7th through today. As the streak of gains continues, investors' eyes are turning to the next resistance level of 30,000 won.
However, given the rapid rise in the stock price over a short period, future volatility also warrants attention. Based on the current trend, whether the stock will recover the 30,000 won level or undergo a correction due to profit-taking and other factors is cited as the key watchpoint for the future share price.
Kolon TissueGene's stock price previously plunged sharply last month related to the first issue concerning the U.S. Phase 3 clinical trial of 'TG-C.' At the time, while pain relief and functional improvement effects were confirmed in the TG-C treatment group, investor sentiment was significantly dampened as statistical significance compared to the placebo control group was not achieved. As the stock price has been showing a rebound since then, attention is focused on how far the current consecutive upward trend will continue.
[This article is by no means an investment recommendation. All investments are made at the discretion of the individual, and the final responsibility lies with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



